Health Economics›Cervical cancer›Definitive therapy for locally advanced disease

Definitive therapy for locally advanced disease

Cervical cancer · 13 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 1 point

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Cisplatin, Pembrolizumab, RT Variant #01	—	R 246 562	42d	—	—	—	—	2
Fluorouracil, Mitomycin, RT Variant #01	—	R 5 688	56d	—	~18.9 mo	—	—	1
Fluorouracil and RT Variant #08	—	R 3 059	77d	—	~17.1 mo	—	—	5
Cisplatin and Gemcitabine (GC) and RT Variant #01	—	R 2 266	42d	—	—	—	—	2
Cisplatin and Fluorouracil (CF) and RT Variant #13	—	R 1 850	28d	—	—	—	—	1
Carboplatin and RT Variant #01	—	R 1 516	42d	—	~22.4 mo	—	—	1
Cisplatin and RT Variant #01	—	R 1 500	49d	~28.0 mo	—	~18	~R 27 004 PFS proxy · indirect	8
Cisplatin and Fluorouracil (CF) and Hydroxyurea, RT Variant #01	—	R 1 146	42d	—	—	—	—	—
Hydroxyurea and RT Variant #01	—	R 385	63d	—	~59.8 mo	—	—	—
Nedaplatin and RT Variant #01 Partial	—	—	—	~30.0 mo	—	—	—	1
Radiation therapy N/A - radiation Partial	—	—	49d	—	—	—	—	3
Brachytherapy protocol Partial	—	—	—	—	—	—	—	—
Brachytherapy Partial	—	—	—	—	—	—	—	—

13 of 13 regimens shown